Fishman Jay A Ltd. MI lifted its holdings in Zoetis Inc (NYSE:ZTS) by 200.4% in the third quarter, Holdings Channel reports. The firm owned 16,338 shares of the company’s stock after buying an additional 10,900 shares during the period. Fishman Jay A Ltd. MI’s holdings in Zoetis were worth $2,036,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Huntington National Bank raised its stake in Zoetis by 3.0% in the 2nd quarter. Huntington National Bank now owns 2,975 shares of the company’s stock worth $338,000 after acquiring an additional 87 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC raised its stake in shares of Zoetis by 1.8% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 4,980 shares of the company’s stock valued at $565,000 after buying an additional 89 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its stake in shares of Zoetis by 0.6% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 15,106 shares of the company’s stock valued at $1,714,000 after buying an additional 89 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Zoetis by 1.4% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 6,720 shares of the company’s stock valued at $837,000 after buying an additional 90 shares during the last quarter. Finally, Intellectus Partners LLC raised its stake in shares of Zoetis by 1.1% during the 2nd quarter. Intellectus Partners LLC now owns 8,040 shares of the company’s stock valued at $912,000 after buying an additional 91 shares during the last quarter. 89.95% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the sale, the executive vice president now directly owns 33,190 shares in the company, valued at approximately $4,181,608.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $128.62, for a total value of $787,540.26. Following the sale, the executive vice president now owns 39,141 shares in the company, valued at $5,034,315.42. The disclosure for this sale can be found here. Insiders have sold a total of 34,332 shares of company stock worth $4,258,182 over the last 90 days. Insiders own 0.29% of the company’s stock.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 7th. The company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same period last year, the firm earned $0.83 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. On average, equities research analysts forecast that Zoetis Inc will post 3.57 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
A number of research firms have weighed in on ZTS. Barclays lifted their price objective on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Argus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Wednesday, September 4th. SunTrust Banks lifted their price objective on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday, August 13th. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Goldman Sachs Group began coverage on Zoetis in a research note on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average target price of $126.75.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Market Capitalization
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.